Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 4/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | GRB2 | P62993 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20768647 | 0.80 | MEN1 (0.38) | CYP2D6CYP2C9HIF1ALMNACYP1A2 | |
| SCHEMBL20768591 | 0.79 | LMNA (0.38) | CYP2D6CYP2C9HIF1ALMNACYP1A2 | |
| SCHEMBL3726388 | 0.77 | CYP1A2 (0.52) | CYP2D6HIF1ACYP1A2MEN1KMT2A | |
| SCHEMBL20768612 | 0.76 | MAP4K4 (0.41) | CYP2D6CYP2C9HIF1ALMNAKMT2A | |
| SCHEMBL20768611 | 0.76 | MAP4K4 (0.41) | CYP2D6CYP2C9HIF1ALMNAKMT2A | |
| SCHEMBL19332273 | 0.71 | PTGS2 (0.55) | CYP2C9LMNAMEN1KMT2A | |
| SCHEMBL20768556 | 0.71 | PTGS2 (0.55) | CYP2C9LMNAMEN1KMT2A | |
| SCHEMBL17085961 | 0.70 | SCN10A (0.46) | LMNAKIF11ANPEPSCN10A | |
| SCHEMBL7761117 | 0.70 | SCN10A (0.46) | LMNAKIF11ANPEPSCN10A | |
| SCHEMBL1444985 | 0.69 | ANPEP (0.41) | CYP2D6HIF1ACYP1A2ANPEPSCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4234552-A2 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3426244-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | CYP2D6 1356/4885CYP2C9 1790/4885HIF1A 1598/4885 |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | CYP2D6 1356/4885CYP2C9 1790/4885HIF1A 1598/4885 |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | CYP2D6 1356/4885CYP2C9 1790/4885HIF1A 1598/4885 |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | CYP2D6 1356/4885CYP2C9 1790/4885HIF1A 1598/4885 |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | CYP2D6 1356/4885CYP2C9 1790/4885HIF1A 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.